World's Best Scientists 2026 revealed!
Leukemia and Lymphoma
H-index 27

Leukemia and Lymphoma

1042-8194

Published by: Taylor & Francis

https://www.tandfonline.com/toc/ilal20/current

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 755 490 789 27

Additional Metrics

Number of Best Scientists*: 679
Documents by Best Scientists*: 932
Top 100 Ranked Scientists*: 13
SCIMAGO H-index: 105
SCIMAGO SJR: 0.778
Impact Factor: 2.2

Overview

Top Research Topics at Leukemia & Lymphoma?

The discussions in Leukemia & Lymphoma mainly cover the fields of Internal medicine, Immunology, Lymphoma, Oncology and Cancer research. The research on Internal medicine tackled can also make contributions to studies in the areas of Gastroenterology and Surgery. It aims to address concerns in Surgery, specifically in the areas of Regimen and Cyclophosphamide.

The research on Immunology featured in Leukemia & Lymphoma combines topics in other fields like Disease and Stem cell. Lymphoma research discussed in it aim to provide more information in the subject of Pathology. The majority of Pathology studies are focused on the issues of Bone marrow.

While work presented in the journal provided substantial information on Oncology, it also covered topics in Refractory, Transplantation and Multiple myeloma. The studies on Cancer research discussed can also contribute to research in the domains of Apoptosis, Haematopoiesis and Gene. The work on Leukemia addressed in Leukemia & Lymphoma expands to the thematically related Myeloid.

  • Internal medicine (38.86%)
  • Immunology (25.32%)
  • Lymphoma (22.93%)

What are the most cited papers published in the journal?

  • Report on the First International Workshop on interim-PET scan in lymphoma (470 citations)
  • Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. (249 citations)
  • CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy (232 citations)

Research areas of the most cited articles at Leukemia & Lymphoma:

The most cited papers mainly deal with areas of study such as Internal medicine, Immunology, Lymphoma, Leukemia and Gastroenterology. The journal publications explore topics in Internal medicine which can be helpful for research in disciplines like Surgery and Oncology. The most cited papers tackle studies in Cancer research and the interrelated subject of Apoptosis to gain insights into Leukemia.

What topics the last edition of the journal is best known for?

  • Internal medicine
  • Cancer
  • Disease

The previous edition focused in particular on these issues:

Leukemia & Lymphoma aims to foster the development of research in Internal medicine, Oncology, Cancer research, Lymphoma and Myeloid leukemia. Studies on Internal medicine discussed in the journal link to the field of Gastroenterology. Concepts in Transplantation, as well as related topics in Stem cell, are covered in the Oncology research presented in Leukemia & Lymphoma.

Some problems in Cancer research that were presented in Leukemia & Lymphoma overlapped with concepts under Cell culture, Chromosomal translocation, Apoptosis and Leukemia, Chronic lymphocytic leukemia. Leukemia & Lymphoma addresses concerns in Lymphoma which are intertwined with other disciplines, such as Clinical trial and Chemotherapy. In addition to Myeloid leukemia research, Leukemia & Lymphoma aims to explore topics under Myeloid and Tyrosine-kinase inhibitor.

The most cited articles from the last journal are:

  • Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. (9 citations)
  • Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. (7 citations)
  • Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. (6 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Leukemia & Lymphoma (based on the number of publications) are:

  • Hagop M. Kantarjian (125 papers) published 5 papers at the last edition, 1 less than at the previous edition,
  • John F. Seymour (92 papers) published 1 paper at the last edition, 4 less than at the previous edition,
  • Morie A. Gertz (84 papers) published 6 papers at the last edition the same number as at the previous edition,
  • Aaron Polliack (74 papers) absent at the last edition,
  • Tadeusz Robak (70 papers) published 2 papers at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Leukemia & Lymphoma (based on the number of publications) are:

  • University of Texas MD Anderson Cancer Center (543 papers) published 37 papers at the last edition the same number as at the previous edition,
  • Mayo Clinic (415 papers) published 25 papers at the last edition, 8 less than at the previous edition,
  • Harvard University (236 papers) published 17 papers at the last edition, 4 less than at the previous edition,
  • Memorial Sloan Kettering Cancer Center (219 papers) published 18 papers at the last edition, 5 less than at the previous edition,
  • Peter MacCallum Cancer Centre (194 papers) published 16 papers at the last edition, 1 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 4.15% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 25.80% were posted by at least one author from the top 10 institutions publishing in the journal. Another 9.79% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 14.31% of all publications and 50.09% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Contributors and Career Opportunities in the Field of Leukemia and Lymphoma Research

Leukemia & Lymphoma research not only involves experts from various disciplines but it also provides a multitude of career opportunities for aspiring researchers. Those interested in advancing their career in this critical field of oncology may find opportunities in academic, clinical and pharmacological research, diagnostic labs, medical writing, consultancy and more.

Nursing is also an integral part of patient care for leukemia and lymphoma. Often, these professionals work in hematology-oncology units in hospitals or specialized cancer treatment centers. Requirements and eligibility for a nursing career in oncology can vary by location. For instance, the kansas nursing license requirements board of nursing requirements provides specific guidelines and requirements for those seeking to practice in Kansas.

The global war against Leukemia and Lymphoma is a concerted effort by numerous dedicated professionals. Each contributor in this field strives to deepen our understanding and improve patient outcomes, ultimately moving us closer to a world free of these devastating diseases.

Top Publications

  • Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

    Neil P Shah;Valentín García-Gutiérrez;Antonio Jiménez-Velasco;Sarah Larson

    (2020)
    123 Citations
  • CPX-351 (vyxeos) in AML

    Mansour Alfayez;Hagop Kantarjian;Tapan Kadia;Farhad Ravandi-Kashani

    (2020)
    82 Citations
  • Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

    Luke Coyle;Nicholas J Morley;Alessandro Rambaldi;Kylie D Mason

    (2020)
    61 Citations
  • Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.

    Nicola Gökbuget;Gerhard Zugmaier;Hervé Dombret;Anthony Stein

    (2020)
    60 Citations
  • Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.

    Sven de Vos;John P Leonard;Jonathan W Friedberg;Jasmine Zain

    (2021)
    55 Citations
  • Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting.

    Jeffrey I Cohen;Keiji Iwatsuki;Young-Hyeh Ko;Hiroshi Kimura

    (2020)
    49 Citations
  • AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial

    (2022)
    49 Citations
  • Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

    (2020)
    46 Citations
  • Venetoclax is safe and efficacious in relapsed/refractory AML

    (2020)
    43 Citations
  • Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

    Srdan Verstovsek;Jingbo Yu;Robyn M. Scherber;Sumit Verma

    (2021)
    37 Citations

Related Online Degrees & Career Pathways

For those interested in healthcare but seeking alternatives to becoming a practicing physician, several related career paths offer promising opportunities. One such field is medical coding, which involves translating healthcare procedures and diagnoses into standardized codes. Understanding the medical coder salary can help you gauge the financial benefits of this career, which remains in demand due to the complexity of healthcare billing systems.

The medical coding job outlook continues to be positive, driven by the growing need for accurate health records and billing. This pathway offers flexible work arrangements, including remote opportunities, making it appealing for many aspiring healthcare professionals.

For those interested in management and administration within healthcare, pursuing a him degree online is a practical option. Health Information Management (HIM) programs provide essential skills in managing patient data, health IT systems, and regulatory compliance.

Additionally, students passionate about nutrition and wellness can explore a master degree in nutrition online. This degree opens doors to careers in clinical nutrition, public health, and wellness coaching, complementing the broader healthcare ecosystem.

Best Scientists Contributing to This Journal

Recently Published Articles